Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: Are there specific patient characteristics or biomarkers to indicate response to treatment?

Kocatürk, EmekBülbül Başkan, EmelEngin, Betül HacerÖzdemir, Mehmet AkifKüçük, Özlem SuCan, PelinÖrnek, SeçilHasal, EdaAtakan, Nilgün2020-03-122020-03-122019Kocatürk, E., Bülbül Başkan, E., Engin, B. H., Özdemir, M. A., Küçük, Ö. S., Can, P. ... Atakan, N. (2019). Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: Are there specific patient characteristics or biomarkers to indicate response to treatment? Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) içinde (484-485. ss.). Lisbon, Portugal, June 01-05, 2019.0105-45381398-9995https://hdl.handle.net/20.500.12511/5029[Abstract Not Available]eninfo:eu-repo/semantics/closedAccessOmalizumab VersusSpontaneous UrticariaSpecific PatientOmalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: Are there specific patient characteristics or biomarkers to indicate response to treatment?Conference Object74Supplement: 106484485Q1